new drugs
neurological diseases


NEU² Partners: Epomedics GmbH

Epomedics GmbH

Rudolf-Wissell-Straße 28
D-37079 Göttingen

Epomedics is a privately held German biopharmaceutical company dedicated to the development of EPO and variants thereof for the treatment of CNS diseases. The demonstration of the applicability of EPO for CNS diseases and the identification of efficacious and safe dosing schemes make it an interesting candidate for a number of diseases that are characterized by a progressive loss of neurons and that have a high medical need. Epomedics holds key patents for the use of EPO in stroke, schizophrenia and multiple sclerosis and also for recently discovered EPO variants showing a comparable mode of action but without being hematopoietic.

Ansprechpartner / Contact person:

Dr. Herbert Stadler
Tel.: +49 551 50672-111
Fax: +49 551 50672-182

Kontakt / Contact:

Zentrale / Main:
Tel.: +49 551 50672-111
Fax: +49 551 50672-182